Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Clear out junk files and repair common Windows errors3Scan for outdated or missing drivers - takes under a minuteSynchron’s Stentrode is an investigational brain-computer interface (BCI) intended to let people with severe motor impairment control digital devices using brain signals. It is delivered through a blood vessel rather than through open skull surgery, but it is still an implanted medical device under clinical investigation—not an approved treatment or a product available to buy. Early human results are promising for feasibility, but come from a very small study and do not establish broad safety or effectiveness.
What is Synchron’s brain implant?
Synchron develops implantable BCIs. Its Stentrode is designed to detect movement-related neural signals and translate them into commands for digital devices. Synchron identifies the United States and Australia as clinical-trial geographies on its technology page.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Brain-Computer Interface Technologies: Accelerating Neuro-Technology for Human Benefit | $93.01 | Buy on Amazon |
| 2 |
|
Brain Computer Interface | $47.24 | Buy on Amazon |
| 3 |
|
Brain Computer Interface | $2.99 | Buy on Amazon |
| 4 |
|
Brain-Computer Interfacing: An Introduction | $44.99 | Buy on Amazon |
The system is intended for people whose severe motor impairment makes operating a computer or tablet difficult or impossible through ordinary movement. It is not a general-purpose device for unrestricted thought control: the published human study examined a limited control system and routine digital activities.
How does the Stentrode work?
In the configuration described in the SWITCH study, a 16-electrode sensing device was placed in the superior sagittal sinus, a blood vessel in the brain. A lead connected it to a receiver-transmitter implanted in a pocket under the skin of the chest. An external telemetry unit relayed signals to a computer or tablet. Those details describe the system studied in SWITCH and should not be assumed to apply unchanged to every current version.
Free tools Windows power users keep installed
One-click scans. No signup required.
#1 Best Overall
The intended sequence is straightforward: neural signals associated with attempted movement are recorded by the implant, relayed outside the body, and used to operate digital controls. Synchron’s current trial page describes control of digital devices, including Apple devices, as an interaction target.
Does Synchron require open brain surgery?
No open skull surgery is described for the Stentrode approach. Synchron says the device is delivered through a catheter inserted into the jugular vein and guided to a brain blood vessel; the route is intended to avoid cutting through the skull. It remains an invasive procedure because it places a device inside the body and in a blood vessel.
Synchron says the procedure used in its clinical trial takes about two hours and that most people go home the next day. That is the company’s description, not a universal timeline or a prediction for an individual patient. The company technology page has the procedure overview.
Rank #2
What has human research shown?
The SWITCH study was a prospective, single-center, first-in-human study in Australia. Five people with severe bilateral upper-limb paralysis enrolled: four had amyotrophic lateral sclerosis (ALS) and one had primary lateral sclerosis. Four participants were included in the reported analysis, and all four completed 12-month follow-up.
Recommended Free Tools
| SWITCH finding | What the study reported |
|---|---|
| Participants | Five enrolled; four included in the analysis (SWITCH authors, JAMA Neurology, 2023). |
| Follow-up | All four analyzed participants completed 12 months (SWITCH authors, JAMA Neurology, 2023). |
| Safety observations | No serious adverse events, vessel occlusion, or device migration were reported among the four analyzed participants during the reported follow-up (SWITCH authors, JAMA Neurology, 2023). |
| Signal bandwidth | Mean 233 Hz (standard deviation 16 Hz), reported as stable over the study period (SWITCH authors, JAMA Neurology, 2023). |
| Activities | Participants used the system for texting, email, personal finance, online shopping, and communicating care needs (SWITCH authors, JAMA Neurology, 2023). |
The study authors summarized their conclusion this way: “These final safety and feasibility data from the first in-human SWITCH study indicate that it is possible to record neural signals from a blood vessel.” The results support early feasibility; four analyzed participants cannot establish how reliably the system will work for a wider population or what risks may emerge with broader use.
Can it help someone with ALS communicate?
The SWITCH participants included people with ALS, and the study reported use for communication-related tasks such as texting, email, and communicating care needs. This is evidence that the system enabled those activities for some participants under study conditions; it is not proof that every person with ALS will qualify, benefit, or use it in the same way. Synchron’s current trial page describes severe bilateral upper-limb weakness as an eligibility category and focuses on restoring motor control over digital devices.
Rank #3
Research beyond SWITCH is ongoing. Synchron’s publication index lists 2025 work on clinical translation, user autonomy, motor activity recorded from Stentrode in two people with ALS, anatomy for endovascular implantation, and signal strength. The index also includes a medRxiv preprint on motor cortex coverage and signal strength; a preprint should not be treated as peer-reviewed evidence.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Is Synchron’s implant FDA approved, and can you buy it?
Synchron states that its BCI is investigational, that clinical benefit has not been validated, and that it is not approved for commercial use in any geography. Stentrode is not available to buy as a consumer device; clinical-trial participation is the route being investigated. The company’s statement is about commercial approval and availability, and does not establish a complete regulatory history for every country or regulator. See Synchron’s FAQ for its current investigational-use statement.
Synchron’s clinical-trials page describes its active research and links to a ClinicalTrials.gov record. Recruitment, trial sites, and eligibility can change, so check the company page and linked registry for current details rather than relying on an older description.
Rank #4
How safe is the Stentrode?
The available SWITCH report is an early safety and feasibility result, not a guarantee. No serious adverse events, vessel blockage, or device migration were reported in the four analyzed participants over their reported 12-month follow-up. That is reassuring within the limits of this small cohort, but it cannot reliably quantify uncommon complications or predict outcomes in different patients, with longer use, or across other device configurations.
Anyone considering trial participation should discuss personal risks, alternatives, follow-up requirements, and eligibility with the trial team and their clinical care providers. The published study and current trial materials, rather than a general device description, are the relevant basis for those decisions.
How to judge Synchron against other BCIs
A fair comparison requires like-for-like evidence, not a blanket ranking based on a company’s description. Useful dimensions include:
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →- Implantation route and procedural invasiveness.
- The population studied and the nature of motor impairment.
- Which control tasks and digital devices were actually used.
- Number of participants, follow-up duration, and which participants were analyzed.
- Reported adverse events and technical performance.
- Regulatory and commercial status in the relevant geography.
The available evidence here does not support a head-to-head claim that Synchron is safer, more capable, or closer to market than another BCI system.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
